Tetanus: The ‘Silent Killer’ That’s Claimed 95% Fewer Newborn Lives in 30 Years
KEY FACTS
- Global tetanus vaccination programs reduced newborn deaths by 95% over the last 30 years, from approximately 200,000 deaths in 2000 to 25,000 in 2018
- In 2023, 84% of infants worldwide received three doses of DTP vaccine, yet nearly 20 million infants failed to complete their primary tetanus vaccination series
- As of June 2024, 10 countries have still not achieved maternal and neonatal tetanus elimination status, defined as less than one case per 1,000 live births in every district
- Without intensive care treatment, nearly 100% of people with tetanus die from respiratory failure, making it one of the deadliest vaccine-preventable diseases
- During 2000–2022, 47 of 59 priority countries achieved maternal and neonatal tetanus elimination, though COVID-19 disruptions caused cases to increase in 18 countries since 2020
In late 1988, WHO estimated that 787,000 newborns died annually from neonatal tetanus—a staggering toll equal to roughly 6.7 deaths per 1,000 live births globally. The disease killed infants within days of birth, their tiny bodies wracked by uncontrollable muscle spasms triggered by contaminated umbilical stumps. Mothers who survived childbirth could still succumb weeks later to the same agonizing fate.
Fast-forward to July 2024, when WHO announced a different statistic: global neonatal tetanus deaths had plummeted to approximately 25,000 annually, a 97% reduction. Yet this triumph of global health efforts comes with an uncomfortable caveat—tetanus remains a “silent killer” in the world’s poorest regions, where unhygienic deliveries and vaccination gaps continue to claim preventable lives.
Unlike diseases WHO can eradicate through vaccination alone, tetanus spores exist permanently in soil worldwide. Elimination doesn’t mean the pathogen disappears; it means vaccination coverage, clean delivery practices, and wound care reach sufficient levels that the disease ceases being a public health problem. But as recent data shows, maintaining that status proves far harder than achieving it in the first place.
This article examines WHO’s data on tetanus, investigates why 10 countries still haven’t reached elimination status despite decades of interventions, and asks whether the maternal and neonatal tetanus elimination initiative can truly protect the world’s most vulnerable populations—or whether progress will continue to stall in conflict zones and underserved communities.
What Is Tetanus? — WHO’s Definition
According to WHO, tetanus is an acute infectious disease caused by spores of the bacterium Clostridium tetani. The disease develops when these spores—ubiquitous in soil, dust, and animal feces worldwide—enter the body through wounds, cuts, burns, or contaminated surgical sites. In neonatal cases, infection occurs when unhygienic practices during childbirth allow bacteria to contaminate the umbilical stump.
WHO reports that once C. tetani spores enter an anaerobic (oxygen-deprived) environment such as a deep wound or necrotic tissue, they germinate and produce tetanospasmin, an extremely potent neurotoxin. This toxin disrupts normal nerve function by preventing the release of inhibitory neurotransmitters, causing the characteristic sustained muscle contractions and spasms that define tetanus.
The disease cannot be transmitted from person to person, WHO emphasizes. Each case results from environmental exposure to the bacteria, making tetanus fundamentally different from contagious infectious diseases. Critically, the organization notes that recovering from tetanus doesn’t confer natural immunity—survivors remain susceptible to reinfection unless vaccinated, since the small amount of toxin that causes disease is insufficient to trigger protective antibody production.
WHO identifies three primary forms based on the affected population: generalized tetanus (the most common form in adults), neonatal tetanus (affecting infants within 28 days of birth), and maternal tetanus (occurring during pregnancy or within six weeks of delivery). The incubation period typically spans 3 to 21 days, with an average of eight days between exposure and symptom onset. Shorter incubation periods generally correlate with more heavily contaminated wounds and worse prognoses.
Global Burden — WHO’s Epidemiological Data
The epidemiological trajectory of tetanus represents one of public health’s most dramatic success stories—and one of its most stubborn remaining challenges. According to WHO’s July 2024 fact sheet, global tetanus deaths declined from an estimated 250,000 annually in the early 1990s to approximately 50,000 by the 2010s. Research published in PMC’s Global Burden of Disease analysis found that childhood tetanus incidence dropped from 308,931 cases in 1990 to 17,788 cases in 2021.
The neonatal tetanus story shows even steeper declines. WHO estimates that neonatal deaths fell from 787,000 in 1988 to 49,000 in 2013, then further to approximately 25,000 in 2018—a 97% reduction over three decades. CDC data from July 2024 confirms that during 2000-2022, reported neonatal tetanus cases decreased 89% and deaths dropped 84% among the 59 priority countries targeted by WHO’s Maternal and Neonatal Tetanus Elimination (MNTE) initiative.
Yet the global burden remains heavily concentrated. Research analyzing Global Burden of Disease Study 2021 data identified the highest tetanus mortality rates in the Caribbean, Central Sub-Saharan Africa, Eastern Sub-Saharan Africa, North Africa and the Middle East, South Asia, Southeast Asia, and Western Sub-Saharan Africa. These regions share common characteristics: low sociodemographic index scores, inadequate sanitation infrastructure, limited access to skilled birth attendants, and vaccination coverage gaps.
The vaccination landscape shows mixed progress. WHO reports that in 2023, 84% of infants worldwide received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine. But that seemingly high figure masks critical gaps—nearly 20 million infants didn’t complete their primary vaccination series that year. Moreover, CDC surveillance data notes that protection at birth (PAB) coverage, which measures maternal vaccination to protect newborns, increased from 74% to 86% globally between 2000 and 2022, leaving 14% of newborns vulnerable.
As of June 2024, WHO’s MNTE initiative reports that 10 countries remain unvalidated for elimination: Afghanistan, Central African Republic, Guinea, Mali, Niger, Nigeria, Pakistan, Somalia, South Sudan, and Yemen. These nations are characterized by ongoing conflict, political instability, displacement, and severely compromised health systems—conditions that make sustained vaccination campaigns and clean delivery practices nearly impossible to implement at scale.
Even in countries that achieved elimination, maintaining that status proves challenging. The COVID-19 pandemic’s disruption of routine immunization services caused reported neonatal tetanus cases to increase in 18 (31%) of the 59 priority countries since 2020. This backsliding mirrors patterns seen in other vaccine-preventable diseases when immunization programs falter, even temporarily. Similar challenges affect efforts to control soil-transmitted helminths and other diseases requiring sustained public health interventions.
Causes, Transmission & Risk Factors — WHO’s Framework
WHO’s epidemiological framework identifies Clostridium tetani as an obligate anaerobic bacterium that produces hardy spores capable of surviving in soil for decades. The organism thrives in environments contaminated by animal or human feces, making agricultural areas with livestock particularly high-risk. The spores are heat-resistant and can withstand standard disinfection procedures, requiring proper sterilization techniques to eliminate them from medical equipment.
Transmission follows a specific biological pathway. According to WHO guidance, when spores enter wounds—particularly deep punctures, crush injuries, burns, or surgical sites—they germinate under anaerobic conditions. The vegetative bacteria then produce two exotoxins: tetanolysin and tetanospasmin. While tetanolysin’s role remains unclear, tetanospasmin is one of the most potent biological toxins known, requiring only 1-2 nanograms per kilogram of body weight to cause symptoms.
The neurotoxin travels retrograde along peripheral nerves to the central nervous system, where it blocks the release of inhibitory neurotransmitters GABA and glycine. This disinhibition causes unopposed motor neuron firing, resulting in the sustained muscle contractions and violent spasms characteristic of tetanus. The toxin’s effects are irreversible—recovery requires new neuromuscular junction formation, explaining why the disease course extends for weeks even with optimal treatment.
WHO documents specific risk factors that dramatically increase tetanus susceptibility. For neonatal tetanus, the primary driver is delivery outside health facilities by unskilled birth attendants using unsterile instruments to cut umbilical cords, combined with application of traditional substances (animal dung, ashes, herbs, or soil) to the umbilical stump. Research in WHO’s African Region identified lack of awareness of antenatal care services, under-utilization of antenatal services, non-immunization with tetanus toxoid vaccines, and negative cultural beliefs about vaccina tion as contributing factors.
For general tetanus, wound characteristics matter enormously. Deep puncture wounds (stepping on nails, injecting drugs), wounds contaminated with soil or feces, compound fractures, crush injuries, burns, and surgical procedures performed in non-sterile conditions all create ideal conditions for spore germination. CDC guidance notes that agricultural workers, older adults with waning immunity, people who inject drugs, and those with diabetes or compromised immune systems face elevated risk.
Vaccination status remains the single most critical risk determinant. WHO emphasizes that unvaccinated individuals, those who didn’t complete the primary vaccination series, and people who haven’t received booster doses every 10 years are highly susceptible. Even in high-income countries, tetanus cases occur primarily among unvaccinated or inadequately vaccinated populations—the disease has virtually disappeared among those maintaining up-to-date immunization.
Signs, Symptoms or Health Impacts — WHO’s Clinical Framework
WHO identifies the classic presentation of generalized tetanus as a descending pattern of muscle involvement, beginning with trismus (lockjaw) as the earliest sign. This jaw muscle rigidity makes opening the mouth progressively more difficult, interfering with eating and speaking. Within days, facial muscle spasms produce risus sardonicus—a characteristic “sardonic smile” caused by sustained contraction of facial muscles into a grotesque grimace.
According to the organization’s clinical guidance, symptoms then progress to the neck, causing stiffness and difficulty swallowing. The spasms spread to abdominal muscles, back muscles (producing opisthotonus, a severe arching of the back), and eventually the extremities. WHO reports that these muscle contractions occur both as sustained rigidity and as sudden, violent spasms lasting several minutes.
The spasms can be triggered by minimal stimuli—loud noises, bright lights, touch, or even drafts of air. During spasms, WHO notes that patients remain fully conscious and experience excruciating pain. The muscle contractions are so powerful they can fracture vertebrae or long bones. When respiratory muscles become involved, patients develop breathing difficulties that can rapidly progress to respiratory failure—the leading cause of death in tetanus cases.
WHO documents autonomic nervous system dysfunction as a dangerous complication occurring in severe cases: labile blood pressure, heart rate irregularities, profuse sweating, and hyperthermia. These cardiovascular instabilities can cause sudden death even in patients receiving intensive care. The organization reports that fever, headache, restlessness, irritability, and difficulty urinating commonly accompany the neuromuscular symptoms.
For neonatal tetanus, WHO describes a different initial presentation. Infants typically appear normal at birth but develop symptoms 3 to 14 days later, averaging around day seven. The first signs are difficulty feeding and excessive crying. Mothers often notice the baby can’t suck properly and becomes increasingly stiff. Within hours to days, generalized muscle rigidity develops, with characteristic flexion of arms, clenched fists, and extended legs.
WHO emphasizes that neonatal tetanus carries an extremely poor prognosis without intensive care. The case fatality rate approaches 100% in settings lacking mechanical ventilation and supportive care. Even with treatment, mortality ranges from 10-60% depending on treatment quality. Survivors may suffer long-term neurological, behavioral, and intellectual impairments from the period of hypoxia and central nervous system damage.
The organization notes that tetanus symptoms persist for 3-4 weeks in typical cases, with spasms gradually decreasing in frequency and severity. Complete recovery takes months, requiring prolonged rehabilitation to regain muscle function and address any complications. WHO stresses that the disease course is unrelenting once symptoms begin—unlike many infections, tetanus doesn’t have a mild form or spontaneously resolve without intervention.
Treatment or Health Response — WHO’s Current Approaches
WHO reports that tetanus requires immediate intensive care treatment, as delaying therapy dramatically worsens outcomes. According to the organization’s clinical protocols, treatment involves four simultaneous components: neutralizing circulating toxin, eliminating the bacterial source, controlling muscle spasms and autonomic dysfunction, and providing supportive care.
Tetanus immune globulin (TIG), also called human tetanus antitoxin, neutralizes toxin that hasn’t yet bound to nerve tissue. WHO notes this must be administered as early as possible since bound toxin is irreversibly damaging. The standard dose is 500 IU intramuscularly, though higher doses (3,000-6,000 IU) may be used for severe cases. However, CDC guidance emphasizes that TIG availability varies globally, and in resource-limited settings, alternatives like equine tetanus antitoxin may be used despite higher risks of allergic reactions.
Wound debridement to remove necrotic tissue and eliminate the anaerobic environment supporting bacterial growth ranks as a critical intervention. WHO recommends thorough surgical cleaning combined with antibiotic therapy—metronidazole is preferred over penicillin due to concerns that penicillin might theoretically worsen spasms by antagonizing GABA receptors. The organization notes that antibiotics don’t reverse existing toxin effects but prevent further toxin production.
Managing muscle spasms presents enormous challenges. WHO reports that benzodiazepines (diazepam, midazolam) serve as first-line therapy, providing both muscle relaxation and sedation. High doses are often required—some patients need continuous infusions. In severe cases unresponsive to benzodiazepines, neuromuscular blocking agents combined with mechanical ventilation become necessary. Clinical research published in StatPearls recommends magnesium sulfate infusions (5g bolus followed by 2-3g/hour) as an adjunct therapy, though careful monitoring for magnesium toxicity is essential.
Autonomic dysfunction management requires intensive monitoring. WHO guidance notes that morphine can help control hypertension, while extreme caution is needed with beta-blockers due to risks of severe hypotension and death. The organization emphasizes that patients need dim, quiet environments since sensory stimuli can trigger lethal spasms.
Supportive care intensity varies dramatically by setting. WHO reports that optimal treatment requires weeks to months in intensive care units with mechanical ventilation, continuous monitoring, nutritional support (tetanus dramatically increases metabolic demands due to constant muscle activity), and prevention of complications like pneumonia, deep vein thrombosis, and pressure ulcers. But these resource-intensive interventions remain unavailable in precisely the regions where tetanus burden is highest.
Access barriers severely limit treatment effectiveness in low-income countries. Research on MNTE progress in WHO’s African Region found that lack of TIG availability, shortage of intensive care beds, limited mechanical ventilation capacity, and insufficient trained healthcare providers all contribute to the high mortality rates. Even where facilities exist, transport delays from remote areas often mean patients arrive too late for effective intervention.
Regional differences in tetanus management reflect these resource disparities. High-income countries report 10-20% case fatality rates with optimal intensive care. Middle-income countries may see 20-40% mortality. In low-income settings without mechanical ventilation, case fatality approaches 80-100%, particularly for neonatal tetanus. WHO acknowledges this inequity as fundamentally unacceptable for a disease entirely preventable through vaccination.
The organization also emphasizes a critical point often misunderstood: surviving tetanus doesn’t provide immunity. WHO requires that all tetanus patients receive full vaccination series during recovery, as the small amount of toxin causing disease is insufficient to trigger protective antibody responses. Without vaccination post-recovery, patients remain fully susceptible to repeat infections.
Prevention & WHO Strategies — Public Health Framework
WHO’s prevention framework for tetanus centers on tetanus toxoid-containing vaccines (TTCV), which the organization describes as among the safest and most effective vaccines available. According to WHO’s immunization guidelines, complete protection requires six doses across the lifespan: three primary doses beginning as early as six weeks of age with minimum 4-week intervals, followed by three booster doses preferably at 12-23 months, 4-7 years, and 9-15 years of age.
The vaccine is administered in combination formulations. WHO lists the available combinations: DTP (diphtheria-tetanus-pertussis) for children, DTaP (diphtheria-tetanus-acellular pertussis) as an alternative primary series, Tdap (tetanus-diphtheria-acellular pertussis) for adolescent boosters, and Td (tetanus-diphtheria) for adult boosters every 10 years. This integration allows protection against multiple diseases simultaneously, improving cost-effectiveness and coverage rates. Recent developments include India’s launch of indigenous tetanus and diphtheria vaccines, reducing dependence on imported vaccine supplies.
For maternal and neonatal tetanus prevention specifically, WHO’s MNTE initiative employs a multi-pronged strategy. Antenatal tetanus vaccination reaches pregnant women through routine immunization programs, with at least two doses of TTCV recommended for previously unvaccinated women to provide protection at birth (PAB). The organization emphasizes that maternal antibodies cross the placenta, protecting newborns during their most vulnerable first months until they can receive their own vaccinations.
In high-risk districts where routine coverage remains inadequate, WHO implements supplementary immunization activities (SIAs) targeting all women of reproductive age (15-49 years) regardless of pregnancy status. CDC data from the MNTE database shows that between 2000 and 2022, these campaigns reached 177 million women in 59 priority countries with at least two doses of tetanus toxoid vaccine.
Clean delivery practices form the second pillar of WHO’s neonatal tetanus prevention strategy. The organization promotes deliveries attended by skilled birth attendants in hygienic settings, use of sterile instruments for cutting umbilical cords, proper cord care with dry cord management (avoiding traditional harmful substances), and education about danger signs requiring medical attention. These practices prove particularly challenging in regions where cultural norms favor home births attended by traditional birth attendants.
Wound care recommendations complete WHO’s prevention framework. The organization advises thorough cleaning of all wounds with soap and water, removal of foreign material and dead tissue, and seeking medical evaluation for wounds that are deep, contaminated with soil or feces, caused by puncture injuries, contain dead tissue, or don’t heal properly. For individuals with uncertain or inadequate vaccination histories sustaining tetanus-prone wounds, WHO recommends both tetanus immune globulin and TTCV vaccination.
Surveillance systems for case identification and investigation help WHO track progress and identify high-risk areas. The organization promotes active case-finding in endemic regions, investigation of every suspected neonatal tetanus death, and regular population-based surveys to assess actual versus reported disease burden. However, WHO acknowledges that notification efficiency for tetanus remains extremely low—perhaps 10% or less—meaning reported cases represent only a fraction of true disease burden.
WHO’s Global Efforts — Recent Initiatives and Editorial Analysis
WHO launched the Maternal and Neonatal Tetanus Elimination initiative in 1999, following decades of slower progress toward goals first articulated in 1989. The target: reduce neonatal tetanus to less than one case per 1,000 live births in every district of every country. This metric defines “elimination as a public health problem” rather than true eradication—a pragmatic acknowledgment that tetanus spores can’t be removed from the environment.
The elimination timeline tells a story of both success and stagnation. When MNTE launched, 59 countries hadn’t achieved elimination. By 2015, the original target date, that number had dropped to 20. By December 2022, CDC’s July 2024 MMWR report confirmed 47 countries (80%) had achieved validated elimination status. But here’s where progress stalled: as of June 2024, according to WHO’s MNTE initiative page, 10 countries remain—the same nations characterized by conflict, insecurity, and state fragility that have challenged every global health initiative.
What happened in those countries that succeeded? MNTE strategies combined aggressive vaccination campaigns with delivery system improvements. WHO and partners conducted supplementary immunization activities reaching women of reproductive age in high-risk districts—often requiring multiple rounds to achieve sufficient coverage. Between 2000 and 2022, these campaigns targeted 252 million women, vaccinating 177 million with at least two doses. Simultaneously, countries invested in training skilled birth attendants, establishing health posts in remote areas, and community education about cord care.
But the numbers reveal uncomfortable truths about sustainability. According to the CDC MMWR analysis, by 2022 only one-third of the 47 validated countries maintained at least 80% TTCV2+ coverage among pregnant women. In 12 validated countries, fewer than 70% of births were assisted by skilled attendants. And fewer than one-third had introduced at least one TTCV booster dose into routine immunization schedules—a critical requirement for long-term protection.
The COVID-19 pandemic laid bare these fragilities. WHO data shows that routine immunization disruptions caused neonatal tetanus cases to increase in 18 countries since 2020—nations that had seemingly controlled the disease suddenly seeing resurgences. This mirrors patterns documented in WHO’s 2024 progress report on Sustainable Development Goals, where multiple health targets faced setbacks during pandemic years.
Recent WHO initiatives attempt to address these vulnerabilities. In September 2023, the organization released a validation protocol for maternal and neonatal tetanus elimination, providing standardized assessment methodology. WHO renewed pharmaceutical partnerships in 2023 for continued vaccine donations to priority countries. The organization also developed updated guidance on maintaining elimination status post-validation, emphasizing integration of tetanus vaccination into routine immunization rather than relying on periodic campaigns.
UNICEF, UNFPA, and WHO jointly coordinate MNTE efforts, leveraging their comparative advantages: UNICEF’s vaccine procurement and cold chain expertise, UNFPA’s reproductive health programming, and WHO’s technical guidance. The partnership claims successes—India’s 2015 elimination validation covered 1.3 billion people, and Indonesia’s 2016 achievement addressed one of Southeast Asia’s most challenging elimination targets. These weren’t small wins; they required years of systematic effort across geographically vast, culturally diverse nations.
Yet here’s the analytical question that nags: if 47 countries eliminated maternal and neonatal tetanus, why can’t the remaining 10? The answer isn’t medical—it’s political and structural. Afghanistan, Central African Republic, Mali, Niger, Nigeria, Pakistan, Somalia, South Sudan, and Yemen share characteristics that make health system strengthening nearly impossible: active armed conflicts, displacement of populations, collapsed governance, chronic underfunding, and competing humanitarian crises. Guinea rounds out the list with similar challenges of extreme poverty and weak infrastructure.
WHO’s messaging around these 10 countries has shifted from optimistic target-setting to pragmatic acknowledgment of barriers. The organization now talks about “ongoing activities” and countries “likely to achieve MNTE in the near future,” but avoids setting firm deadlines. It’s a recognition that technical interventions—however well-designed—can’t overcome the fundamental prerequisites of functional states and stable populations.
The broader question is whether MNTE’s framework adequately addresses tetanus burden beyond maternal and neonatal populations. WHO’s focus on mothers and newborns makes epidemiological sense—that’s where the disease burden concentrates in low-income countries. But as countries develop, the disease pattern shifts toward older adults with waning immunity and marginalized populations without healthcare access. WHO’s expanded vision talks about “protecting all,” yet adult booster coverage remains poor even in high-income nations.
What should WHO do differently? The MNTE experience suggests that integration matters more than campaigns. Countries that embedded tetanus vaccination into routine antenatal care and childhood immunization schedules sustained elimination. Those relying on periodic supplementary activities saw coverage fluctuate with funding cycles. WHO’s technical guidance acknowledges this, but implementation requires sustained domestic financing that priority countries struggle to mobilize.
The organization could also push harder on equity metrics. Current WHO monitoring emphasizes national or district-level elimination status, but within-country disparities remain masked. Urban-rural gaps, ethnic minority exclusion, and socioeconomic stratification all affect who receives vaccination and skilled birth attendance. WHO’s Sustainable Development Goal framework theoretically addresses these inequities, but MNTE reporting doesn’t routinely disaggregate data to expose them.
Perhaps most critically, WHO needs honest conversation about what “elimination” means when it can’t be sustained. If validated countries slide backward during crises—whether COVID-19, conflict, or economic collapse—was elimination truly achieved or merely temporarily measured? The 18 countries showing increased cases since 2020 suggest the latter. Maybe WHO needs different terminology: sustained elimination versus fragile elimination, with different monitoring requirements for each category.
For the 10 countries remaining, perhaps 2030 targets should pivot from elimination validation toward harm reduction: maximizing vaccination coverage in accessible populations, strengthening surveillance to identify outbreaks quickly, ensuring TIG availability for treatment, and accepting that complete elimination may require prior resolution of conflicts and state-building—preconditions beyond WHO’s mandate.
The tetanus elimination story shows what’s possible when vaccines, political will, and resources align. It also shows what happens when that alignment falters. WHO’s next roadmap should grapple more explicitly with that tension rather than maintaining the fiction that technical solutions alone can solve problems rooted in state fragility and inequality.
Frequently Asked Questions
Yes. According to WHO, recovering from tetanus doesn’t provide immunity against future infections. The small amount of bacterial toxin that causes disease is insufficient to trigger protective antibody production. This means survivors remain fully susceptible to tetanus unless they receive complete vaccination after recovery. WHO requires all tetanus patients to be vaccinated during or shortly after treatment to prevent repeat infections.
WHO reports that tetanus commonly causes sustained contraction of jaw muscles (trismus), making it difficult or impossible to open the mouth. This “locking” of the jaw is often the first symptom people notice and the most characteristic sign of the disease. The jaw rigidity interferes with eating, speaking, and swallowing, and can progress to involve facial muscles, creating a grimacing expression called risus sardonicus.
According to WHO immunization guidelines, complete tetanus protection requires six doses across the lifespan: three primary doses in infancy, followed by three booster doses in childhood and adolescence. After completing this series, WHO recommends booster doses every 10 years throughout adulthood to maintain immunity. Without boosters, protection gradually wanes, leaving people increasingly susceptible to infection from contaminated wounds.
No. WHO emphasizes that tetanus cannot be transmitted from one person to another under any circumstances. Each case results from individual exposure to Clostridium tetani spores in the environment—typically through contaminated wounds, but also through unhygienic practices during childbirth or medical procedures. The disease is an infection, not a communicable condition, which fundamentally shapes prevention strategies focusing on vaccination rather than isolation.
WHO data shows the 10 countries that haven’t eliminated maternal and neonatal tetanus share common barriers: armed conflicts and instability preventing vaccination campaigns, lack of skilled birth attendants forcing home deliveries in unhygienic conditions, cultural practices involving contamination of umbilical stumps, extreme poverty limiting healthcare access, and weak health systems unable to maintain routine immunization coverage. Eliminating the disease requires sustained peace, functioning governance, and healthcare infrastructure—prerequisites these countries currently lack.
Sources
- World Health Organization. Tetanus fact sheet. July 12, 2024. https://www.who.int/news-room/fact-sheets/detail/tetanus
- Centers for Disease Control and Prevention. Progress Toward Achieving and Sustaining Maternal and Neonatal Tetanus Elimination — Worldwide, 2000–2022. MMWR. July 18, 2024. https://www.cdc.gov/mmwr/volumes/73/wr/mm7328a1.htm
- World Health Organization. Maternal and Neonatal Tetanus Elimination (MNTE) initiative. https://www.who.int/initiatives/maternal-and-neonatal-tetanus-elimination-(mnte)
- Global analysis of tetanus incidence and mortality in children under 5 years: findings from the Global Burden of Disease Study 2021. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12083341/
- Centers for Disease Control and Prevention. Fast Facts: Global Tetanus Vaccination. November 17, 2025. https://www.cdc.gov/global-tetanus-vaccination/data-research/index.html
DISCLAIMER
This article adapts publicly available information from WHO’s Tetanus page. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform — not a healthcare provider.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
